INTRA-TUMOR MOLECULAR HETEROGENEITY OF CLEAR CELL RENAL CELL CARCINOMA SEEMS TO CONTRIBUTE TO THE DIVERSITY OF RESPONSE TO TARGETED THERAPIES

Baoan Hong,Yong Yang,Sheng Guo,Qixiang Li,Ning Zhang,Kan Gong

DOI: https://doi.org/10.1016/j.juro.2018.02.2153

2018-01-01

European Urology Supplements

Abstract:You have accessJournal of UrologyKidney Cancer: Basic Research & Pathophysiology I1 Apr 2018PD46-05 INTRA-TUMOR MOLECULAR HETEROGENEITY OF CLEAR CELL RENAL CELL CARCINOMA SEEMS TO CONTRIBUTE TO THE DIVERSITY OF RESPONSE TO TARGETED THERAPIES Baoan Hong, Yong Yang, Sheng Guo, Qixiang Li, Ning Zhang, and Kan Gong Baoan HongBaoan Hong More articles by this author , Yong YangYong Yang More articles by this author , Sheng GuoSheng Guo More articles by this author , Qixiang LiQixiang Li More articles by this author , Ning ZhangNing Zhang More articles by this author , and Kan GongKan Gong More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2153AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Inter- and intra-tumor molecular heterogeneity is increasingly recognized in clear cell renal cell carcinoma (ccRCC). It could, in part, explain the diversity of responses to targeted therapies and the varied clinical outcomes observed for histologically similar tumors. The present study aimed to examine intra-tumor molecular heterogeneity in primary and metastatic ccRCC tissues and their responses to targeted therapies. METHODS A ccRCC patient with multiple metastases received radical nephrectomy and resection of the metastatic tumor in chest wall. Meanwhile, the specimens were implanted into immunedeficient mice to establish Patient-Derived Xenografts (PDXs), with KI2367 derived from primary tumor and KI2368 from metastasis. KI2367 and KI2368 was transcriptome sequenced and treated with Sorafenib, Sunitinib, Axitinib, combined Sorafenib/Sunitinib, or alternating therapy of Sorafenib/Sunitinib. RESULTS Sorafenib/Sunitinib monotherapy, combined or alternating treatment groups demonstrated more significant anti-tumor activity, as compared to Axitinib monotherapy (P<0.05). Most interestingly, the PDX of KI2368, in contrast to KI2367, demonstrated significant anti-tumor activity to Sunitinib monotherapy, Sorafenib and Sunitinib combination and alternating treatment groups, but not to Sorafenib or Axitinib monotherapy (P<0.05). A total of 1725 genes have > 5-fold higher expression levels in KI2367 than in KI2368, including the relevant drug targets: PDGFA, PDGFB and PDGFRA. A total of 994 genes have > 5-fold higher expression in KI2368 than in KI2367. Against human reference genome, 5539 and 5827 protein change variants were respectively found in KI2367 and KI2368, 4023 common variants in both samples. We also found 20 and 4 in-frame gene fusions in KI2367 and KI2368, but no common in-frame fusion was detected. CONCLUSIONS These results suggest the presence of the intra-tumor molecular heterogeneity in this patient, which could influence the clinical outcome of targeted therapies. Multiple biopsy and genomic analysis of intra-tumor molecular heterogeneity could potentially help guide more effective plan in selecting targeted therapies for ccRCC patients. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e892-e893 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Baoan Hong More articles by this author Yong Yang More articles by this author Sheng Guo More articles by this author Qixiang Li More articles by this author Ning Zhang More articles by this author Kan Gong More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...